Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®)-A case report

Clin Case Rep. 2022 Jan 20;10(1):e05272. doi: 10.1002/ccr3.5272. eCollection 2022 Jan.


Rhabdomyolysis (RM) is a potentially life-threatening entity that can lead to acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) alone is known as effective therapy, but the additional use of a hemoadsorber (like CytoSorb®) might increase its efficacy.

Keywords: CytoSorb®; acute kidney injury; myoglobin; renal replacement therapy; rhabdomyolysis.

Publication types

  • Case Reports